



Network of Rare Blood Disorder
Organizations
Réseau des Associations Vouées
aux Troubles Sanguins Rares

September 30, 2019

Rt. Hon. Justin Trudeau, P.C., M.P., Leader of the Liberal Party of Canada
Hon. Andrew Scheer, P.C., M.P., Leader of the Conservative Party of Canada
Jagmeet Singh, M.P., Leader of the New Democratic Party of Canada
Yves-François Blanchet, Leader of the Bloc Québécois
Elizabeth May, M.P., Leader of the Green Party of Canada

Dear Sirs and Madam,

As we head to the polls on October 21, the Network of Rare Blood Disorder Organizations and our twelve member organizations are eager to hear from each of you on an issue that is important to us: access to innovative therapies for people with rare disorders.

While most aspects of public healthcare fall to the provinces and territories, the federal government plays a crucial role in setting drug policies that can impact our country's ability to attract clinical trials, investments in drug research, and new therapies. It is imperative that in securing fair prices for therapies to treat common conditions, we do not jeopardize access to therapies for Canadians with rare disorders, including rare blood disorders.

Canada needs federal leadership if we are to continue to be among the first in the world to receive access to innovative therapies. Therefore, in advance of the upcoming election, we would appreciate your response to the following question:

If elected, how will your party ensure Canadians with rare disorders receive timely, equitable access to life-changing innovative therapies?

We thank you in advance for your response. If received by October 14, we will make your response available to our membership before Canadians head to the polls.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Erin Harder'.

Erin Harder
Acting Chair, Network of Rare Blood Disorder Organizations